Match!
Ioannis Prassas
Mount Sinai Hospital, Toronto
CancerMolecular biologyMedicineBiomarker (medicine)Biology
37Publications
14H-index
961Citations
What is this?
Publications 40
Newest
#1Phedias Diamandis (U of T: University of Toronto)H-Index: 10
#2Ioannis Prassas (MSH: Mount Sinai Hospital, Toronto)H-Index: 14
Last. Eleftherios P. DiamandisH-Index: 99
view all 3 authors...
Source
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Marco Iafolla (UHN: University Health Network)
Last. Anna Spreafico (UHN: University Health Network)H-Index: 5
view all 13 authors...
Background: Validated biomarkers are needed to identify patients at increased risk of immune-related adverse events (irAEs) to immune checkpoint blockade (ICB). Antibodies directed against endogenous antigens can change after exposure to ICB. Methods: Patients with different solid tumors stratified into cohorts received pembrolizumab every 3 weeks in a Phase II trial (INSPIRE study). Blood samples were collected prior to first pembrolizumab exposure (baseline) and approximately 7 weeks (pre-cycl...
Source
#1Panagiota Filippou (U of T: University of Toronto)H-Index: 16
#2Annie H. Ren (U of T: University of Toronto)
Last. James Conner (U of T: University of Toronto)H-Index: 2
view all 7 authors...
Abstract Objectives Kallikrein-related peptidases (KLKs) are a subgroup of 15 secreted chymotrypsin- and trypsin-like serine proteases that have been reported to possess novel functions in innate immunity and inflammation. Since the potential role of KLKs in immunity has not been studied in detail at the protein level, we examined the expression pattern of 12 members of the KLK family in immune-related tissues. Design & Methods Protein expression in tissue extracts was evaluated using immunoassa...
Source
1 CitationsSource
#1Bryant Lim (U of T: University of Toronto)H-Index: 1
#1Bryant Lim (U of T: University of Toronto)
Last. Eleftherios P. Diamandis (U of T: University of Toronto)H-Index: 99
view all 7 authors...
Background: Recent efforts have described an immunogenic component to the pathobiology of Alzheimer’s disease (AD) and Parkinson’s disease (PD). However, current methods of studying fluid autoantibodies, such as enzyme-linked immunosorbent assays and immunohistochemistry, are hypothesis-driven and not optimal for discovering new autoantibody biomarkers by proteome-wide screening. Recently, we developed a general mass spectrometry-based approach to identify tissue-specific autoantibodies in serum...
Source
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Antoninus Soosaipillai (MSH: Mount Sinai Hospital, Toronto)H-Index: 35
Last. Eleftherios P. DiamandisH-Index: 99
view all 6 authors...
In the original version of the article [1], an error was noticed under the heading “Immunoprecipitation on protein G magnetic beads” in “Methods” section.
Source
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Antoninus Soosaipillai (MSH: Mount Sinai Hospital, Toronto)H-Index: 35
Last. Eleftherios P. DiamandisH-Index: 99
view all 6 authors...
Background Autoantibodies are produced when tolerance to self-antigens is broken and they can be mediators of tissue injury and systemic inflammation. They are excellent biomarkers because they are minimally invasive to screen and are highly abundant in serum due to limited proteolysis and slow clearance. Conventionally used methods of identifying autoantibodies in patient sera include indirect immunofluorescence, enzyme-linked immunoabsorbent assays (ELISAs) and protein microarrays. Here we pre...
1 CitationsSource
Source
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Ioannis Prassas (MSH: Mount Sinai Hospital, Toronto)H-Index: 14
Last. Eleftherios P. Diamandis (Lunenfeld-Tanenbaum Research Institute)H-Index: 99
view all 3 authors...
AbstractCancer immunotherapy, a treatment that selectively augments a patient’s anti-tumor immune response, is a breakthrough advancement in personalized medicine. A subset of cancer patients undergoing immunotherapy have displayed robust and long-lasting therapeutic responses. Currently, the spotlight is on the use of blocking antibodies against the T-cell checkpoint molecules, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programed cell death-1 (PD-1)/programed death-ligand 1 (PD-L1...
3 CitationsSource
#1Panagiota Filippou (U of T: University of Toronto)H-Index: 16
#2Annie H. Ren (U of T: University of Toronto)
Last. Eleftherios P. DiamandisH-Index: 99
view all 8 authors...
Abstract Objective Human tissue kallikrein 15 (KLK15) is the last cloned member of the KLK-related gene family. Despite being implicated in multiple cancers, its pathophysiological role remains unknown. We aimed to biochemically characterize KLK15 and preliminarily study its role in cancer. Design & methods Recombinant KLK15 protein was produced, purified to homogeneity and quantified by mass spectrometry (parallel reaction monitoring analysis). We profiled the enzymatic activity of KLK15 using ...
Source
1234